Last reviewed · How we verify
Combination - Tranilast and Allopurinol
Tranilast inhibits the activity of mast cells and platelets, while Allopurinol inhibits xanthine oxidase.
Tranilast inhibits the activity of mast cells and platelets, while Allopurinol inhibits xanthine oxidase. Used for Gout, Allergic rhinitis.
At a glance
| Generic name | Combination - Tranilast and Allopurinol |
|---|---|
| Sponsor | Nuon Therapeutics, Inc. |
| Drug class | mast cell stabilizer, xanthine oxidase inhibitor |
| Modality | Small molecule |
| Therapeutic area | Rheumatology, Allergy |
| Phase | Phase 2 |
Mechanism of action
Tranilast is a mast cell stabilizer that inhibits the release of histamine and other mediators from mast cells, which are involved in allergic reactions and inflammation. Allopurinol, on the other hand, is a xanthine oxidase inhibitor that reduces the production of uric acid, which is associated with gout and other conditions.
Approved indications
- Gout
- Allergic rhinitis
Common side effects
- Nausea
- Diarrhea
- Headache
- Dizziness
- Fatigue
Key clinical trials
- Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO) (PHASE2)
- Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |